Legend Biotech's LB2501 shows 100% response in aggressive lymphoma trial
Legend Biotech's LB2501 shows 100% response in aggressive lymphoma trial
Legend Biotech's LB2501 shows 100% response in aggressive lymphoma trial
Legend Biotech has announced the first clinical proof-of-concept data for LB2501, its experimental in vivo CAR-T cell therapy. The treatment targets both CD19 and CD20 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (RR B-NHL). Early results show strong efficacy and a promising safety profile. LB2501 is part of an ongoing Phase 1 study assessing safety, tolerability, and preliminary efficacy in patients with relapsed or refractory B-cell malignancies. At the higher dose level (DL2), the therapy achieved a 100% objective response rate (ORR) and an 83.3% complete response rate (CR) in RR B-NHL patients. All responses at this dose level were still ongoing at the time of data cutoff.
The therapy demonstrated a favourable safety profile, with no dose-limiting toxicities, serious adverse events, immune effector cell-associated neurotoxicity syndrome, or deaths reported. A single infusion of LB2501 also produced dose-dependent in vivo CAR-T expansion without the need for lymphodepletion.
B-cell lymphomas make up around 85% of non-Hodgkin lymphoma cases, a group of cancers originating in lymphocytes. Legend Biotech, a leader in cell therapy, aims to transform cancer care through innovative treatments like LB2501. The early data for LB2501 suggests high efficacy and a strong safety record in treating RR B-NHL. The ongoing Phase 1 study will continue to evaluate its potential. Legend Biotech remains focused on expanding access to advanced therapies like CARVYKTI while developing new solutions for cancer patients.